

Message

From: Tegeris, John (OS/ASPR/BARDA) (CTR) [john.tegeris@hhs.gov]
Sent: 5/25/2017 7:34:57 PM
To: Bright, Rick (OS/ASPR/BARDA) [Rick.Bright@hhs.gov]; Disbrow, Gary (OS/ASPR/BARDA) [Gary.Disbrow@hhs.gov]; Schafer, Julie (OS/ASPR/BARDA) [Julie.Schafer@hhs.gov]; Maher, Carmen (FDA/OC) [Carmen.Maher@fda.hhs.gov]; Sadove, Elizabeth (FDA/OC) [Elizabeth.Sadove@fda.hhs.gov]; Ross, Jennifer (FDA/OC) [Jennifer.Ross@fda.hhs.gov]; Nalubola, Ritu (FDA/OC) [Ritu.Nalubola@fda.hhs.gov]; Flamm, Eric (FDA/OC) [Eric.Flamm@fda.hhs.gov]; Zborowsky, Ashley (FDA/OC) [Ashley.Zborowsky@fda.hhs.gov]; Epstein, Laura (FDA/CVM) [Laura.Epstein@fda.hhs.gov]; Hartman, Mark [Hartman.Mark@epa.gov]; McNally, Robert [Mcnally.Robert@epa.gov]; Mendelsohn, Mike [Mendelsohn.Mike@epa.gov]; Milewski, Elizabeth [Milewski.Elizabeth@epa.gov]; Wozniak, Chris [wozniak.chris@epa.gov]; Jennings, Susan [Jennings.Susan@epa.gov]; Layne, Arnold [Layne.Arnold@epa.gov]; Rosenblatt, Daniel [Rosenblatt.Dan@epa.gov]; Petersen, Lyle (CDC/OID/NCEZID) [lxp2@cdc.gov]; Beard, Charles (Ben) (CDC/OID/NCEZID) [cbb0@cdc.gov]; Koonin, Lisa (CDC/OID/NCIRD) [lmk1@cdc.gov]; Kovacs, Gerald (OS/ASPR/BARDA) (CTR) [Gerald.Kovacs@hhs.gov]; Costero-Saint Denis, Adriana (NIH/NIAID) [E] [acostero@niaid.nih.gov]; Leissa, Brad G (FDA/CDER) [Brad.Leissa@fda.hhs.gov]; Lueptow, Rebekka (HHS/ASPR/BARDA) [Rebekka.Lueptow@hhs.gov]; Wolf, Laura (OS/ASPR/OEM) [Laura.Wolf@hhs.gov]; Curren, Stephen (OS/ASPR/OEM) [Stephen.Curren@hhs.gov]; Little, James (OS/ASPR/BARDA) [James.Little@hhs.gov]; Leahy, John [Leahy.John@epa.gov]; Shimkin, Martha [Shimkin.Martha@epa.gov]; Tegeris, John (OS/ASPR/BARDA) (CTR) [john.tegeris@hhs.gov]
Subject: FINAL MEETING SUMMARY: FDA and EPA Edits Included; Interagency Meeting with Oxitec/Intrexon Group, Wed May 17, 10am-12pm ET
Attachments: Summary_Interagency Meeting with Oxitec_051717_FDA_EPA_Final.docx

Hi All,

I feel confident this final version that includes ALL edits from comments received from FDA and EPA, respectively, will ensure my full release from the collective regulatory doghouse I have taken up residence in since the first meeting summary was sent out last Fri (haha). This meeting summary is meant to be an informal overview of what transpired with Oxitec/Intrexon and is not intended for distribution beyond those included here nor to the company itself. Hopefully this checks the box on what really was a very good interagency meeting, which we believe proved value-added to the Oxitec/Intrexon group. Thanks again to everyone for being a part of this necessary process. Your BARDA colleagues wish each of you and your families a fabulous upcoming holiday weekend!

Best Wishes,
John

Ex. 6 - Personal Privacy